Novo Nordisk is losing a key obesity figure. Lotte Bjerre Knudsen, a decorated GLP-1 pioneer, is retiring.
Knudsen’s exit closes a career at the center of GLP-1 drug development. For a company that built its dominance on that science, losing a decorated pioneer to retirement is expected.
Diana Kowalski
Lilly paid $3.25 billion upfront for Kelonia Therapeutics, with total deal value reaching up to $7 billion in milestones.
Venrock put $20 million into Kelonia Therapeutics.
Lilly paid an undisclosed sum upfront for Kelonia Therapeutics on Monday, placing a large bet on in vivo CAR-T as its next platform priority.